Benralizumab

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ex-smokers with severe asthma, according to data published in The Journal of Allergy and Clinical Immunology: In Practice.

SAN FRANCISCO — Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a poster presented at the American Thoracic Society International Conference.

SAN FRANCISCO — Patients with asthma who did not persist with biologic treatment had more exacerbations and used more oral corticosteroids, according to an abstract presented at the American Thoracic Society International Conference.

SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here.

SAN DIEGO — Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here.

SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.

In this video, Rula Hajj-Ali, MD discusses the latest developments in the study and treatment of vasculitis.

Among adults with severe eosinophilic asthma and previous biologic use, benralizumab for 48 weeks aided in reducing exacerbations and improving asthma symptom control, according to results published in European Respiratory Journal.

Receiving a benralizumab injection during an acute asthma or COPD exacerbation with a blood eosinophil count of at least 300 cells/µL led to fewertreatment failures, according to results published in The Lancet Respiratory Medicine.

BOSTON — Patients taking benralizumab experienced more asthma exacerbations than patients taking mepolizumab, according to an abstract presented at the CHEST Annual Meeting.